Molecular markers in gliomas: impact for the clinician.
Over the last decade, understanding of glioma on a molecular level has greatly expanded. However, optimal incorporation of molecular markers into clinical care is controversial. We briefly review the potential utility of molecular stratification in refining histologic diagnosis, prognosis, and treatment decisions, focussing on 1p/19q co-deletion, MGMT promoter methylation, EGFR mutations, and IDH mutation. The most recently discovered IDH mutation is a striking example of a rapid implementation of a molecular marker for prognostication into common clinical use.
Hofer
Silvia
S
Department of Oncology, University Hospital Zürich, Zürich, Switzerland. Silvia.Hofer@usz.ch
Lassman
Andrew B
AB
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics*; D001932:Brain Neoplasms / Q000235:genetics* / Q000378:metabolism; D005910:Glioma / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D009363:Neoplasm Proteins / Q000235:genetics*; D010597:Pharmacogenetics; D011379:Prognosis
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins
J Neuropathol Exp Neurol. 2001 Sep;60(9):863-71
11556543
Neurology. 1989 Jun;39(6):789-96
2725874
Clin Cancer Res. 2007 Dec 1;13(23):6933-7
18056167
Ann Neurol. 1988 Apr;23(4):360-4
3382171
Nature. 2008 Oct 23;455(7216):1061-8
18772890
Clin Cancer Res. 2010 Mar 1;16(5):1597-604
20160062
Brain. 2007 Oct;130(Pt 10):2596-606
17785346
J Natl Cancer Inst. 1993 May 5;85(9):704-10
8478956
Acta Neuropathol. 2009 Oct;118(4):469-74
19554337
Neuro Oncol. 2007 Jul;9(3):314-8
17435180
Lancet Neurol. 2009 Sep;8(9):810-8
19665931
Brain Pathol. 2002 Apr;12(2):257-9
11958379
J Neuropathol Exp Neurol. 2006 Sep;65(9):846-54
16957578
Ann Neurol. 1998 Oct;44(4):691-5
9778271
J Clin Oncol. 2006 Jun 20;24(18):2707-14
16782910
J Clin Oncol. 2010 Jun 1;28(16):2712-8
20439646
N Engl J Med. 1980 Dec 4;303(23):1323-9
7001230
Brain Pathol. 2008 Jul;18(3):360-9
18371182
J Clin Oncol. 2010 Apr 20;28(12):2051-7
20308655
J Clin Oncol. 1994 Oct;12(10):2013-21
7931469
J Clin Oncol. 2009 Dec 10;27(35):5881-6
19901104
J Natl Cancer Inst. 2005 Jun 15;97(12):880-7
15956649
J Mol Med (Berl). 2005 Nov;83(11):917-26
16133418
J Neurooncol. 2007 Apr;82(2):175-6
17008949
Cancer Res. 2004 Oct 1;64(19):6892-9
15466178
Ann Neurol. 1990 May;27(5):573-4
2360797
Arch Pathol Lab Med. 2007 Feb;131(2):242-51
17284109
J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9
9776413
N Engl J Med. 2005 Mar 10;352(10):997-1003
15758010
Endocr Relat Cancer. 2001 Jun;8(2):83-96
11397666
Acta Neuropathol. 2007 Aug;114(2):97-109
17618441
Cancer. 2003 Mar 1;97(5):1276-84
12599236
J Clin Oncol. 2004 Jan 1;22(1):133-42
14638850
Cancer. 2005 Oct 1;104(7):1468-77
16088966
Clin Cancer Res. 2008 Feb 15;14(4):957-60
18281526
Nat Rev Cancer. 2004 Apr;4(4):296-307
15057289
J Neuropathol Exp Neurol. 2007 Jun;66(6):545-51
17549014
Neuro Oncol. 2010 Mar;12(3):289-96
20167817
Virchows Arch. 2008 May;452(5):481-90
18351387
Neuro Oncol. 2009 Feb;11(1):69-79
18772354
Neuro Oncol. 2010 Jan;12(1):95-103
20150372
Am J Pathol. 1994 Nov;145(5):1175-90
7977648
J Clin Oncol. 2009 Dec 10;27(35):5874-80
19901110
Lancet Oncol. 2009 May;10(5):459-66
19269895
Clin Transl Oncol. 2010 Apr;12(4):310-4
20462843
J Clin Oncol. 2009 Dec 10;27(35):5861-2
19901101
Nature. 2009 Dec 10;462(7274):739-44
19935646
J Clin Oncol. 2009 Aug 10;27(23):3861-7
19506159
Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1372-80
18355978
Am J Pathol. 1999 Aug;155(2):375-86
10433931
J Neurooncol. 2010 Sep;99(2):283-6
20146086
Cancer. 1997 Apr 1;79(7):1381-93
9083161
Neurology. 2004 Jun 8;62(11):2113-5
15184628
J Clin Oncol. 2000 Feb;18(3):636-45
10653879
J Neuropathol Exp Neurol. 2004 Apr;63(4):314-22
15099021
Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):51-5
9422557
Neurology. 2010 Jun 8;74(23):1886-90
20427748
Ann Neurol. 2006 Dec;60(6):740-3
17192931
J Neurooncol. 2008 Jul;88(3):293-8
18345516
Acta Neuropathol. 2001 Apr;101(4):311-20
11355302
PLoS Med. 2006 Dec;3(12):e485
17177598
J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62
11245209
Clin Cancer Res. 2009 Nov 1;15(21):6683-93
19861461
Acta Neuropathol. 2009 Sep;118(3):401-5
19543740
Neuro Oncol. 2010 Oct;12(10):1061-70
20615922
Brain Pathol. 2008 Oct;18(4):520-32
18400046
Target Oncol. 2010 Sep;5(3):161-5
20725792
J Clin Oncol. 2009 Sep 1;27(25):4150-4
19636000
Science. 2009 Apr 10;324(5924):261-5
19359588
J Clin Oncol. 2007 Jun 1;25(16):2288-94
17538175
Cancer Cell. 2006 Mar;9(3):157-73
16530701
J Neurooncol. 2010 May;98(1):93-9
19960228
Neurology. 2001 Oct 9;57(7):1278-81
11591848
J Neurosurg. 1978 Sep;49(3):333-43
355604
J Clin Oncol. 2009 Mar 10;27(8):1268-74
19204207
J Clin Oncol. 2006 Jun 20;24(18):2715-22
16782911
N Engl J Med. 2009 Feb 19;360(8):765-73
19228619
N Engl J Med. 2005 Nov 10;353(19):2012-24
16282176
Clin Cancer Res. 2001 Apr;7(4):839-45
11309331
J Clin Oncol. 2006 Jun 1;24(16):2563-9
16735709
Cancer Res. 2006 Oct 15;66(20):9852-61
17047046
J Clin Oncol. 2010 Apr 20;28(12):e188-9; author reply e190-2
20159801
Clin Cancer Res. 2005 Nov 1;11(21):7841-50
16278407
N Engl J Med. 2005 Mar 10;352(10):987-96
15758009
Neuro Oncol. 2010 Feb;12(2):116-21
20150378